Current CDC surveillance through late May 2026 confirms no active Level 4 Travel Health Notices, with all alerts limited to Level 1 or 2 for widespread dengue and Level 3 for Ebola Bundibugyo in the Democratic Republic of the Congo. Official monitoring by the National Center for Emerging and Zoonotic Infectious Diseases shows no extreme health risks meeting the “Avoid All Travel” threshold, as case trajectories and transmission patterns remain below criteria for such designations. Lower-level advisories for chikungunya and measles continue without escalation signals in recent model runs or observational data. Traders price “No” at 76% given the absence of rapid deterioration in any monitored outbreak and typical seasonal patterns through year-end. Continuous CDC updates on case thresholds and geographic spread will shape any shifts.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日はい
$71,730 Vol.
$71,730 Vol.
2026/12/31
はい
$71,730 Vol.
$71,730 Vol.
2026/12/31
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Current CDC surveillance through late May 2026 confirms no active Level 4 Travel Health Notices, with all alerts limited to Level 1 or 2 for widespread dengue and Level 3 for Ebola Bundibugyo in the Democratic Republic of the Congo. Official monitoring by the National Center for Emerging and Zoonotic Infectious Diseases shows no extreme health risks meeting the “Avoid All Travel” threshold, as case trajectories and transmission patterns remain below criteria for such designations. Lower-level advisories for chikungunya and measles continue without escalation signals in recent model runs or observational data. Traders price “No” at 76% given the absence of rapid deterioration in any monitored outbreak and typical seasonal patterns through year-end. Continuous CDC updates on case thresholds and geographic spread will shape any shifts.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
マーケット開始日： Jan 19, 2026, 3:15 PM ET
音量
$71,730終了日
2026/12/31マーケット開始日
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Current CDC surveillance through late May 2026 confirms no active Level 4 Travel Health Notices, with all alerts limited to Level 1 or 2 for widespread dengue and Level 3 for Ebola Bundibugyo in the Democratic Republic of the Congo. Official monitoring by the National Center for Emerging and Zoonotic Infectious Diseases shows no extreme health risks meeting the “Avoid All Travel” threshold, as case trajectories and transmission patterns remain below criteria for such designations. Lower-level advisories for chikungunya and measles continue without escalation signals in recent model runs or observational data. Traders price “No” at 76% given the absence of rapid deterioration in any monitored outbreak and typical seasonal patterns through year-end. Continuous CDC updates on case thresholds and geographic spread will shape any shifts.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
音量
$71,730終了日
2026/12/31マーケット開始日
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...Current CDC surveillance through late May 2026 confirms no active Level 4 Travel Health Notices, with all alerts limited to Level 1 or 2 for widespread dengue and Level 3 for Ebola Bundibugyo in the Democratic Republic of the Congo. Official monitoring by the National Center for Emerging and Zoonotic Infectious Diseases shows no extreme health risks meeting the “Avoid All Travel” threshold, as case trajectories and transmission patterns remain below criteria for such designations. Lower-level advisories for chikungunya and measles continue without escalation signals in recent model runs or observational data. Traders price “No” at 76% given the absence of rapid deterioration in any monitored outbreak and typical seasonal patterns through year-end. Continuous CDC updates on case thresholds and geographic spread will shape any shifts.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問